The last year and a half has been exceptionally challenging for life sciences companies. We have seen many companies struggle to raise money while simultaneously tighten budgets, lay off their employee base, explore multiple alternative avenues for financing, and become more focused on priority programs to extend their runways.
With sentiment in the biopharma market improving during the second quarter of 2023, Co-hosts Bob and David Crean of Innovation Wave, explore what they are seeing in the market regarding supply and demand, private capital Venture financing, public market IPO’s and follow financings, and mergers and acquisitions (M&A).
Bob and David remain optimistic about the environment going forward. The fundamentals of the ecosystem are strong with robust recovery anticipated in H2 2023 and early 2024.
